Data provided by Nasdaq. Minimum 15 minutes delayed.
December 07, 2016
NantHealth And TransMed Systems Partner to Enable and Inform Community Oncologists of the Most Effective Tools and Technologies for Personalized Cancer Treatments Using GPS Cancer™
Collaboration will provide access to data around real-time outcomes including clinical trial matches and cost analysis to the network of community cancer centers treating patients with rare and common cancers CULVER CITY, Calif.--(BUSINESS WIRE)--Dec. 7, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company and TransMed Systems, a company that develops and deploys software solu...
December 06, 2016
NantHealth Announces Exclusive Reseller Agreement for GPS Cancer™ with Oncotest-Teva in Israel
Company continues strong momentum for its comprehensive molecular test for cancer care and driving the era of clinical proteomics by landing first international distributor relationship CULVER CITY, Calif. & SHOHAM, Israel--(BUSINESS WIRE)--Dec. 6, 2016-- NantHealth, Inc., (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, today announced that it has entered into an exclusive reseller agreement for GP...
December 05, 2016
NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Molecular Profiling to Patients in the Middle East Through Partnership with Lunatus
Oncologists in United Arab Emirates, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon will be empowered to make more informed clinical decisions to personalize treatment and care for their patients Partnership builds on international expansion of GPS Cancer which was recently made available in Italy and Israel CULVER CITY, Calif. & DUBAI, United Arab Emirates--(BUSINESS WIRE)--Dec. 5, 2016-- NantHealth, Inc., (Nasdaq: NH), a...
|There are currently no events scheduled.|